VANCOUVER, British Columbia, November 14, 2022 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) announces that it has entered into an agreement dated for reference November 10, 2022 with Sunfits Investments Ltd., to settle debt in the amount of $345,000 owed pursuant to a consulting agreement dated April 1, 2019 in exchange for the issuance of 2,300,000 common shares at a deemed price of 15 cents per share. All securities issued are subject to a statutory hold period expiring on November 15, 2023.

Read more ...

VANCOUVER, British Columbia, September 7, 2022 -- Biocure Technology Corp. (“Biocure” or the “Company”) (CSE:CURE) is pleased to provide the following operational and investment update to the market and its stakeholders.

BiocurePhram Corp. in Korea (“BPK”), a subsidiary of the Company in Korea has been awarded a grant of KRW40 million (approx. CAD38,120 per the exchange rate on Sep. 6, 2022, Bank of Canada) by Daejeon Technopark Foundation (“DTF”), a local government agency supporting a local business with innovative technologies. BPK is supposed to contribute 10% of the granted amount out of its own treasury to receive the grant.

Read more ...

VANCOUVER, British Columbia, December 2nd, 2021 -- Biocure Technology Corp. (“Biocure” or the “Company”) (CSE:CURE; OTCQB: BICTF) is pleased to provide the following operational and investment update to the market and its stakeholders.

The Company continues to build financial value within Cancer Treatment through two ways; 

• Development of it’s own pipeline products with potential for the Company to secure a number of patents covering revolutionary Car-T bi-specific therapies in the near term.
• Building value through partnering with strategic players and licencees (non-dilutive funding).
  
  

Read more ...

VANCOUVER, British Columbia, August 30th, 2021 -- BioCure Technology Inc. (CSE:CURE; OTCQB: BICTF; FSE: 1WH) (“BioCure” or the “Company”) is pleased to provide the following corporate update;

BiocurePharm Corp. ("BPK"), a subsidiary of the Company is excited to announce its focus on the development of its own CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers. BPK is using an innovative concept of ROR1 CAR T-cell therapy combined with a double specific antibody model. In conjunction with the development of its own CAR T, the Company plans to apply for patents covering this CAR T-cell cancer therapy technology.

Read more ...

VANCOUVER, British Columbia, August 3^rd, 2021 -- BioCure Technology Inc.,(CSE:CURE OTCQB:BICTF FSE:1WH ) - BioCure Technology Inc. (“BioCure” or the “Company”) is pleased to announce listing on the Frankfurt Stock Exchange as of August 2, 2021 and the completion of an issuer sponsored research report by Pitt Street Research.

Read more ...

VANCOUVER, British Columbia, July 22^nd, 2021 -- Biocure Technology Corp. (CURE or the Company) (CSE:CURE; OTCQB: BICTF)  – BioCure Technology Inc., is pleased to announce that Björn Cochlovius, Ph.D, Assoc.Prof., has joined BioCure Technology Inc. as President. We are also pleased to announce that Diverse Capital Pte Ltd (“Diverse Capital”) has been appointed as a Capital Markets Advisor.

Read more ...

Vancouver, British Columbia – BioCure Technology Inc. (CSE: CURE) (“BioCure” or the “Company”) announces that it has successfully closed a non-brokered private placement (the “Private Placement”) consisting of 6,706,525 Units at a price of $0.16 cents per Unit for gross proceeds of $1,073,044.00

Read more ...

VANCOUVER, British Columbia, June 28th, 2021 -- Biocure Technology Corp. (CURE or the Company) (CSE:CURE; OTCQB: BICTF) is pleased to announce that it has started with its dual listing on the Frankfurt Stock Exchange. As the Company is seeing increased investor interest due to its potential European partnerships with Symbasis GmbH in Germany and S&R Biopharm in Bulgaria and as it plans to move towards it’s Car-T trials later this year, the Company believes the dual listing of its shares in Frankfurt will increase the ability for European investors to become shareholders in the Company. The Company also expects to see increased liquidity in it’s shares as a result of the dual listing.

Read more ...

VANCOUVER, British Columbia, February 16^th, 2021-- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) is pleased to announce that Mr. Berkan Unal has joined the Board of Directors as an Independent Director, effective immediately. He will replace Mr. Hans Frykman, whom was a valuable asset to our Board for 3 years. We wish him continued success and thank him for his service.

Read more ...

VANCOUVER, British Columbia, January 4th , 2021 -- Biocure Technology Corp. (CURE or the Company) (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea (BPK), a subsidiary of Biocure Technology Inc. (CURE) is pleased to announce that BPK has entered into a MOU with Symbasis GmbH. They have expressed a common interest in developing a CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL) and wish to sign this MOU for the purpose of confirming their intention in respect to the development.

Read more ...

VANCOUVER, British Columbia, December 29th, 2020 -- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea (“BPK”), a subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that BiocurePharm Korea (“BPK”) and Pharos Vaccine Inc. (“PVI”) have jointly submitted an Investigational New Drug (“IND”) application to the Korean Ministry of Food and Drug Safety (“KFDS”) to proceed with clinical trial Phase 1 for CD19 CAR-T therapy to treat Acute Lymphocyte Leukemia (“ALL”).  

Read more ...

Vancouver, British Columbia – BioCure Technology Inc. (CSE: CURE) (“BioCure” or the “Company”) announces that it will close a non-brokered private placement (the “Private Placement" on October 15th, 2020 consisting of 1,786,725 Units at a price of $0.14 cents per Unit for gross proceeds of $250,142.

Read more ...